Arcus Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $247.0 | $258.0 | $117.0 | $112.0 | $383.0 |
| Operating income | -$386.0 | -$330.0 | -$340.0 | -$280.0 | $54.0 |
| Net income | -$353.0 | -$283.0 | -$307.0 | -$267.0 | $53.0 |
| Balance Sheet | |||||
| Total debt | $100.0 | $50.0 | $0.0 | — | — |
| Cash Flow Statement | |||||
| Free cash flow | -$484.0 | -$176.0 | -$330.0 | $432.0 | -$282.0 |
Shares outstanding 127.3M · Free float 63.1%
Annual filing data through FY ended December 31, 2025; float as of September 12, 2026.